Busca avançada
Ano de início
Entree


Extracellular vesicles produced by immunomodulatory cells harboring OX40 ligand and 4-1BB ligand enhance antitumor immunity

Texto completo
Autor(es):
Semionatto, Isadora Ferraz ; Palameta, Soledad ; Toscaro, Jessica Marcelino ; Manrique-Rincon, Andrea Johanna ; Ruas, Luciana Pereira ; Paes Leme, Adriana Franco ; Bajgelman, Marcio Chaim
Número total de Autores: 7
Tipo de documento: Artigo Científico
Fonte: SCIENTIFIC REPORTS; v. 10, n. 1, p. 10-pg., 2020-09-16.
Resumo

Genetically modified tumor cells harboring immunomodulators may be used as therapeutic vaccines to stimulate antitumor immunity. The therapeutic benefit of these tumor vaccines is extensively investigated and mechanisms by which they boost antitumor response may be further explored. Tumor cells are large secretors of extracellular vesicles (EVs). These EVs are able to vehiculate RNA and proteins to target cells, and engineered EVs also vehiculate recombinant proteins. In this study, we explore immunomodulatory properties of EVs derived from antitumor vaccines expressing the TNFSF ligands 4-1BBL and OX40L, modulating immune response mediated by immune cells and eliminating tumors. Our results suggest that the EVs secreted by genetically modified tumor cells harboring TNFSF ligands can induce T cell proliferation, inhibit the transcription factor FoxP3, associated with the maintenance of Treg phenotype, and enhance antitumor activity mediated by immune cells. The immunomodulatory extracellular vesicles have potential to be further engineered for developing new approaches for cancer therapy. (AU)

Processo FAPESP: 17/06692-2 - Desenvolvimento de novos receptores de células T a partir do isolamento de sequências obtidas de linfócitos infiltrados em sítios tumorais, provenientes de animais tratados com imunomoduladores
Beneficiário:Marcio Chaim Bajgelman
Modalidade de apoio: Auxílio à Pesquisa - Regular
Processo FAPESP: 19/04458-8 - Desenvolvimento de nanopartículas biológicas para potencialização da resposta imune antitumoral
Beneficiário:Marcio Chaim Bajgelman
Modalidade de apoio: Auxílio à Pesquisa - Regular
Processo FAPESP: 18/16449-0 - Engenharia de nanopartículas multifuncionais alvo-dirigidas para eliminação de células tumorais
Beneficiário:Isadora Ferraz Semionatto
Modalidade de apoio: Bolsas no Brasil - Doutorado